Acid Alpha Mannosidase Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Acid Alpha Mannosidase Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Acid alpha-mannosidase (also known as lysosomal alpha-mannosidase or MAN2B1) is a crucial lysosomal hydrolase enzyme encoded by the [MAN2B1](/genes/man2b1) gene. This enzyme catalyzes the hydrolysis of terminal alpha-mannose residues from mannose-containing oligosaccharides, playing an essential role in glycoprotein catabolism within lysosomes. Deficiency of this enzyme causes alpha-mannosidosis, a rare lysosomal storage disorder. [@borgwardt2015]
Infobox
{.infobox .infobox-protein} [@malm2008]
Structure
Acid alpha-mannosidase is a lysosomal hydrolase with the following structural features:
Precursor Form: 1,001 amino acid precursor
Proteolytic Processing: Cleaved into heavy chain (~70 kDa) and light chain (~30 kDa)
N-glycosylation: Multiple N-linked glycosylation sites essential for proper folding and lysosomal targeting
Mannose-6-phosphate Tags: Required for lysosomal trafficking via mannose-6-phosphate receptors
Active Site: Contains catalytic residues for mannose hydrolysis
The enzyme requires optimal acidic pH (around 4.5-5.0) for activity, consistent with the lysosomal environment.
Normal Function
Acid alpha-mannosidase plays a critical role in glycoprotein catabolism:
Oligosaccharide Degradation: Hydrolyzes terminal alpha-1,2-, alpha-1,3-, and alpha-1,6-linked mannose residues from N-linked glycans
Glycoprotein Turnover: Essential for normal degradation of glycoproteins in the lysosome
Cellular Homeostasis: Prevents accumulation of mannose-rich oligosaccharides
The enzyme works in concert with other lysosomal hydrolases to completely degrade complex N-linked glycoproteins.
Role in Disease
Alpha-Mannosidosis
Deficiency of acid alpha-mannosidase leads to accumulation of mannose-rich oligosaccharides in lysosomes throughout the body, particularly affecting:
Central Nervous System: Accumulation in [neurons](/entities/neurons) leads to intellectual disability, ataxia, and developmental delays
Cochlea: Accumulation causes hearing loss
Bone: Storage leads to dysostosis multiplex and skeletal abnormalities
Disease Severity: Correlates with residual enzyme activity - patients with <1% activity have severe phenotype, while 1-10% activity shows milder disease.
Therapeutic Targeting
Enzyme Replacement Therapy (ERT): Recombinant human alpha-mannosidase (Velmanase alfa) approved for treating alpha-mannosidosis
Bone Marrow Transplant: Can provide donor-derived enzyme-producing cells
Gene Therapy: Experimental approaches using viral vectors to deliver functional MAN2B1
Substrate Reduction Therapy: Experimental approaches to reduce substrate accumulation
Chaperone Therapy: Small molecule chaperones to enhance residual enzyme activity
Key Publications
[Desnick et al., Enzyme replacement therapy for alpha-mannosidosis (2004)](https://doi.org/10.1016/j.ymgme.2004.12.017)
[Borgwardt et al., Clinical efficacy of velmanase alfa (2015)](https://doi.org/10.1186/s13023-015-0284-9)
The study of Acid Alpha Mannosidase Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.